Article prepared by the Palmetto Peptides Research Team
, ,
The primary antibodies that were used were as follows: antibodies against cardiac troponin T (#ab209813, 1: 3000 for cardiomyocytes), antibodies against Col11 (#ab270993, 1:2000), antibodies against Vimentin (#ab24525, 1:300) and cardiac troponin T (#ab8295, 1: 2000 for myocardial tissue) were obtained from Abcam (Cambridge, UK)
When IGF-1 is expressed in a muscle-restricted, locally acting form, it can sustain myocyte hypertrophy and preserve age-independent regenerative capacity without the systemic pathology associated with whole-body IGF-1 elevation
doi: 10.3389/fimmu.2024.1476859 Received 06 August 2024 Accepted 03 December 2024 Published 19 December 2024 Volume 15 - 2024 Edited by Carmelo Carmona-Rivera, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH), United States Reviewed by Jos Jiram Torres-Ruiz, National Institute of Medical Sciences and Nutrition Salvador Zubirn, Mexico Matteo Doglio, San Raffaele Hospital (IRCCS), Italy Lauren Robinson, Hospital for Special Surgery, United States Updates Copyright 2024 Zhou, Lei, Shi, Luo, Wu, Xu, Zhang, Liu, Wang, Zhou and He
